Covista Inc.
boothcheck covers Covista Inc. (CVSA) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Essentially all revenue is tuition, split across three healthcare-focused schools: Chamberlain at $197.0 million of March-quarter revenue, Walden at $186.6 million, and the medical and veterinary schools at $103.5 million. • The dominant risk is federal rather than commercial, and the 10-K says so directly: ⟦"Our ability to comply with several ED regulations is not entirely within our control"⟧, and a programme failing the government's outcomes test twice in three years loses access to federa
Is CVSA overvalued? See what's priced in →
341 institutional managers reported holding CVSA in 13F filings for the quarter ended 2026-03-31. 38 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 1.6M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (6.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CVSA has cut its share count 31% over the past five years, spending $962.21M on repurchases. It pays no dividend. Cash returned over the past three years: $714.96M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CVSA over the trailing three years: 2025: 3 buys totaling $229k; 2026: 4 buys totaling $3.75M. 23 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CVSA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-11 | -1.1% | +0.7% |
| 2023-10-27 | +12.4% | +18.1% |
| 2024-01-31 | +5.2% | +1.8% |
| 2024-05-03 | +18.9% | +13.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CVSA's latest 8-K filings: 2026-09-23 (items 1.01, 2.03, 9.01); 2026-08-06 (items 2.02, 9.01); 2026-07-28 (items 5.02, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-04-09 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.